HMPL-760

DRUG3 trials

Sponsors

Hutchmed

Conditions

B-Cell Non-Hodgkin's LymphomaCLL/SLLDLBCLFollicular LymphomaLymphoplasmacytic LymphomaMCLMZLNHL

Phase 1

HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL

WithdrawnNCT05176691

HutchmedCLL/SLL, DLBCL, Follicular Lymphoma +6

Start: 2022-02-15End: 2022-11-16Updated: 2023-02-21

HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

CompletedNCT05190068

HutchmedB-Cell Non-Hodgkin's Lymphoma

Start: 2022-01-04End: 2025-01-27Updated: 2025-04-09

Phase 3

A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL

RecruitingNCT07409428

HutchmedRelapsed/Refractory Diffuse Large B-Cell Lymphoma

Start: 2026-03-20End: 2028-12-30Target: 240Updated: 2026-04-01

Related Papers

Abstract 4020: HMPL-760 is a highly potent and selective reversible BTK inhibitor, targeting BTK and BTKC481S in B-cell malignancies

Cancer Research2023-04-042 citations

PB1880: A MULTICENTER PHASE 1 STUDY EVALUATING THE SAFETY AND TOLERABILITY OF HMPL-760 IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA OR OTHER NON-HODGKIN LYMPHOMA

HemaSphere2022-06-01